Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1
Transitioning off C5i treatment
- Administer Aspaveli twice weekly in addition to the patient’s current dose of C5i treatment for the first 4 weeks1
- After 4 weeks of concomitant therapy, discontinue C5i treatment and start Aspaveli monotherapy for the duration of therapy1
Dose adjustments
- For LDH levels greater than 2x the ULN, the dosing regimen may be adjusted to 1080 mg every 3 days1
- In the event of a dose increase, monitor LDH twice-weekly for at least 4 weeks1
Missed doses
Administer Aspaveli as soon as possible after a missed dose. Resume the regular dosing schedule following administration of the missed dose1
PP-20361